Self-Administered Etripamil Nasal Spray Relieved Symptoms, Decreased Heart Rate, and Reduced Medical Interventions During Atrioventricular Nodal-Dependent Paroxysmal Supraventricular Tachycardia
Circ Arrhythm Electrophysiol
.
2024 Dec;17(12):e011681.
doi: 10.1161/CIRCEP.123.011681.
Epub 2024 Nov 27.
Authors
Bruce S Stambler
1
,
Benoit Coutu
2
,
James E Ip
3
,
Blandine Mondésert
4
,
A Shekhar Pandey
5
,
Philip T Sager
6
,
Doug Wight
7
,
Francis Plat
7
,
Silvia Shardonofsky
7
,
David B Bharucha
7
,
A John Camm
8
Affiliations
1
Cardiac Arrhythmia Research and Education, Piedmont Heart Institute, Atlanta, GA (B.S.S.).
2
Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada (B.C.).
3
Clinical Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, NY (J.E.I.).
4
Electrophysiology Service, Montreal Heart Institute, University de Montréal, Montréal, QC, Canada (B.M.).
5
Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada (A.S.P.).
6
Cardiovascular Research Institute & Department of Medicine, Stanford University, Palo Alto, CA (P.T.S.).
7
Milestone Pharmaceuticals, Montreal, QC, Canada (D.W., F.P., S.S., D.B.B.).
8
Clinical Cardiology, St. George's University of London, London, United Kingdom (A.J.C.).
PMID:
39601141
DOI:
10.1161/CIRCEP.123.011681
No abstract available
Keywords:
calcium channel blockers; heart rate; nasal sprays; tachycardia.
Publication types
Letter